Cyient DLM Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9g5bf42bj0pex188eyf3rduc.pdf

Key Takeaways


Order Book & Demand Pipeline

Montalbano: "I would definitely expect to have some very solid updates within the next quarter for sure."

Segment Performance & Mix Shift

SegmentTrendCommentary
Aerospace & Defense▲ GrowingHigher share of revenue in FY24 vs FY23; driven by general increase in global defense funding, not specifically Middle East tension. Opportunities in Middle East and India.
Industrial▼ DeclinedDecline due to a key client degrowing; recovery expected as new clients come on board.
Medical/Healthcare▬ Early stageWorking on key opportunities; a key client announcement expected. Significant upside potential and new logos anticipated throughout FY25.
Exports▲ Mix improvingExport share higher in Q4; expected to shift from 66-34 to 70-30 in FY25, supporting margin improvement.

Margins & Profitability

Kulkarni: "Our decision making will be the return on capital employed rather than margins."

Balance Sheet & Cash Flow


Strategic Initiatives & Investments

Montalbano: "We see this as having what I call material impact going forward as we continue to add capability, capacity, and also potential geo-offerings."

Segment Mix Ambition

Montalbano: "Ideally, we would like to get it where 25% of the business is 25% medical, 25% industrial, and then maybe A and B make up 50%."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue CAGRMaintain 30% on a three-year basisRolling three-year basis
Order backlog rebuild"Very solid updates" expectedWithin the next quarter
EBITDA marginFull-year improvement year-on-year, but not reaching 11–12%; sequential softness in early quartersFY25 [10-11]
Export mixShift from 66-34 to 70-30FY25
Working capitalMaintain net working capital cycle of 90–100 daysEnd of FY25
Finance costsExpected to declineOver the next year
ROCE target~15%Within a couple of years [16-17]
ROCE target (steady state)~25%In about 5 years
Inorganic updateAnnouncement on acquisition targetNext earnings call [12-13]
Segment mix target25% medical, 25% industrial, 50% A&DIn about 2–3 years

Key Metrics

MetricQ4 FY24
Revenue₹361.8 cr, +30.5% YoY
Full-year revenue₹1,191.9 cr, +43.2% YoY
Operating profit₹38 cr, +19.2% YoY
EBITDA margin10.5%
Profit after tax₹22.7 cr, +80.7% YoY
PAT margin6.3%, +175 bps YoY
Order backlog₹2,170.5 cr, down ₹262 cr YoY
Order backlog-to-sales ratio~1.8x, vs ~2.9x at end of FY23 (per an analyst's math)
Order wins~half of prior-year order wins
Net working capital79 days, lowest in four quarters
Average net working capital (full year)>100 days
DSO57 days
Free cash flow (Q4)~₹129 cr positive
Free cash flow (full year)negative ₹104 cr
Fixed asset turnover8.6x, improved from 6.8x
Export-to-domestic revenue mixTwo-thirds export, one-third domestic
Defense segment revenue share56% of total, segment grew ~78%
Box build share of order book25%, down from 35% in FY24
BEL order book remaining~₹5.5 cr, down from ~₹95 cr at start of FY24
Customer advances25 days of advances
Revenue seasonality~45% H1, ~55% H2
ROCE target~15% within a couple of years, ~25% steady state
Inorganic sweet spot$40 mn to $100 mn annual revenue
Ideal segment mix target (2–3 years)25% medical, 25% industrial, 50% aero & defense